The potential role of appetite in predicting weight changes during treatment with olanzapine

BMC Psychiatry

Volumn 10, Issue , 2010, Pages

  Case, Michael ^a   Treuer, Tamas ^b   Karagianis, Jamie ^b,c   Hoffmann, Vicki P ^a  

^a Lilly USA   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADULT; AGED; APPETITE; ARTICLE; BIPOLAR DISORDER; CLINICAL ASSESSMENT; CLINICAL STUDY; CONTROLLED STUDY; DECREASED APPETITE; DRUG USE; EATING HABIT; FEMALE; FOOD PREFERENCE; HUMAN; INCREASED APPETITE; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PREDICTION; PROSPECTIVE STUDY; PSYCHOLOGICAL RATING SCALE; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; WEIGHT CHANGE; WEIGHT GAIN; COMPARATIVE STUDY; DRUG EFFECT; FEEDING BEHAVIOR; FOOD INTAKE; LIFESTYLE; MIDDLE AGED; PHASE 4 CLINICAL TRIAL; PHYSIOLOGY; PROBABILITY; PSYCHOLOGICAL ASPECT; PSYCHOLOGY; STATISTICS;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; APPETITE; APPETITE REGULATION; BENZODIAZEPINES; CLINICAL TRIALS, PHASE IV AS TOPIC; FEEDING BEHAVIOR; FEMALE; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; PROBABILITY; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; WEIGHT GAIN;

EID: 77956493182     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-10-72     Document Type: Article

References (26)

1. Matsui-Sakata A, Ohtani H, Sawada Y. Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet 2005, 20:368-378. 10.2133/dmpk.20.368, 16272755.
2. Starrenburg FC, Bogers JP. How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins. Eur Psychiatry 2009, 24:164-170. 10.1016/j.eurpsy.2009.01.001, 19285836.
3. Palik E, Birkas KD, Faludi G, Karadi I, Cseh K. Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics. Diabetes Res Clin Pract 2005, 68(Suppl 1):S60-S64. 10.1016/j.diabres.2005.03.008, 15955378.
4. Weston-Green K, Huang XF, Han M, Deng C. The effects of antipsychotics on the density of cannabinoid receptors in the dorsal vagal complex of rats: implications for olanzapine-induced weight gain. Int J Neuropsychopharmacol 2008, 11:827-835. 10.1017/S1461145708008560, 18257959.
5. Baptista T, Zarate J, Joober R, Colasante C, Beaulieu S, Paez X, Hernandez L. Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics. Curr Drug Targets 2004, 5:279-299. 10.2174/1389450043490514, 15058313.
6. Chintoh AF, Mann SW, Lam L, Lam C, Cohn TA, Fletcher PJ, Nobrega JN, Giacca A, Remington G. Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration. J Clin Psychopharmacol 2008, 28:494-499. 10.1097/JCP.0b013e318184b4c5, 18794643.
7. Sharpe JK, Stedman TJ, Byrne NM, Wishart C, Hills AP. Energy expenditure and physical activity in clozapine use: implications for weight management. Aust N Z J Psychiatry 2006, 40:810-814.
8. Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment - Pharmacological mechanisms. Pharmacol Ther 2009,
9. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003, 28:519-526. 10.1038/sj.npp.1300027, 12629531.
10. Knolle-Veentjer S, Huth V, Ferstl R, Aldenhoff JB, Hinze-Selch D. Delay of gratification and executive performance in individuals with schizophrenia: putative role for eating behavior and body weight regulation. J Psychiatr Res 2008, 42:98-105. 10.1016/j.jpsychires.2006.10.003, 17126365.
11. Cserjesi R, Luminet O, Poncelet AS, Lenard L. Altered executive function in obesity. Exploration of the role of affective states on cognitive abilities. Appetite 2009, 52:535-539. 10.1016/j.appet.2009.01.003, 19260167.
12. Kluge M, Schuld A, Himmerich H, Dalal M, Schacht A, Wehmeier PM, Hinze-Selch D, Kraus T, Dittmann RW, Pollmacher T. Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study. J Clin Psychopharmacol 2007, 27:662-666. 10.1097/jcp.0b013e31815a8872, 18004133.
13. Theisen FM, Linden A, Konig IR, Martin M, Remschmidt H, Hebebrand J. Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine. J Neural Transm 2003, 110:111-121.
14. Sentissi O, Viala A, Bourdel MC, Kaminski F, Bellisle F, Olie JP, Poirier MF. Impact of antipsychotic treatments on the motivation to eat: preliminary results in 153 schizophrenic patients. Int Clin Psychopharmacol 2009, 24:257-264. 10.1097/YIC.0b013e32832b6bf6, 19606055.
15. Stauffer VL, Lipkovich I, Hoffmann VP, Heinloth AN, McGregor HS, Kinon BJ. Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis. BMC Psychiatry 2009, 9:12. 10.1186/1471-244X-9-12, 2667505, 19327167.
16. Hardy T, Henry RR, Forrester TD, Kryzhanovskaya LA, Watson SB, Marks DM, Mudaliar S. Insulin Sensitivity in Patients with Schizophrenia or Schizoaffective Disorder Treated with Olanzapine or Risperidone [abstract]. Presented at APA San Francisco 2007,
17. Treuer T, Hoffmann VP, Chen AK, Irimia V, Ocampo M, Wang G, Singh P, Holt S. Factors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: results from a six-month prospective, multinational, observational study. World J Biol Psychiatry 2009, 10:729-740. 10.1080/15622970903079507, 19606406.
18. Karagianis J, Grossman L, Landry J, Reed VA, de Haan L, Maguire GA, Hoffmann VP, Milev R. A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: the PLATYPUS Study. Schizophr Res 2009, 113:41-48. 10.1016/j.schres.2009.05.024, 19535229.
19. Poole Hoffman V, Case M, Jacobson JG. Algorithms Including Amantadine, Metformin and Zonisamide for Mitigation of Weight Gain During Olanzapine Treatment in Outpatients with Schizophrenia [abstract]. Presented at APA San Francisco 2007 2009,
20. Stunkard AJ, Messick S. The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger. J Psychosom Res 1985, 29:71-83. 10.1016/0022-3999(85)90010-8, 3981480.
21. White MA, Whisenhunt BL, Williamson DA, Greenway FL, Netemeyer RG. Development and validation of the food-craving inventory. Obes Res 2002, 10:107-114. 10.1038/oby.2002.17, 11836456.
22. Kinon BJ, Kaiser CJ, Ahmed S, Rotelli MD, Kollack-Walker S. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol 2005, 25:255-258. 10.1097/01.jcp.0000161501.65890.22, 15876905.
23. Cooper G, Goudie A, Halford J. Acute effects of olanzapine on behavioural expression including the behavioural satiety sequence in female rats. J Psychopharmacol 2009,
24. Baptista T, Contreras Q, Teneud L, Albornoz MA, Acosta A, Paez X, de QM, LaCruz A, Hernandez L. Mechanism of the neuroleptic-induced obesity in female rats. Prog Neuropsychopharmacol Biol Psychiatry 1998, 22:187-198. 10.1016/S0278-5846(97)00101-2, 9533175.
25. Karagianis J, Hoffmann VP, Arranz B, Treuer T, Maguire GA, de HL, Chawla B. Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain. Hum Psychopharmacol 2008, 23:275-281. 10.1002/hup.933, 18338426.
26. Treuer T, Karagianis J, Hoffmann VP. Can increased food intake improve psychosis? A brief review and hypothesis. Curr Mol Pharmacol 2008, 1:270-272. 10.2174/1874467210801030270, 20021439.